Bristol-Myers Squibb Stock Forecast for 2022 - 2025 - 2030
Updated on 05/25/2022
If the average 2022 price target of $78.00 recently set by sixteen prominent experts for Bristol-Myers Squibb is met, there would be a potential upside of approximately 1.13% from the last closing price in May, 2022. The high estimate is $94.00, and the low is $63.00. If you're looking for information on Bristol-Myers Squibb stock, consider checking out the forecasts for comparable firms such as NasdaqGS:AMGN.
1.13% Upside
Bristol-Myers Squibb Fair Value Forecast for 2022 - 2025 - 2030
In the past three years, Bristol-Myers Squibb's Fair Value has seen significant growth, rising from $48.28 to $91.10 – a growth of 88.69%. In the next year, analysts believe that Fair Value will reach an unimpressive $93.89 – an increase of 3.06%. By 2030, professionals predict that Bristol-Myers Squibb's Fair Value will decrease by 8.79%, to a mere $83.09.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
3
|
$181.40 | $187.12 | 1.98% | 16 |
| PFE Stock Forecast | Pfizer | Outperform |
7
|
$53.41 | $58.26 | 2.98% | 16 |
| ROG Stock Forecast | Roche Holding | Outperform |
3
|
CHF346.20 | CHF384.23 | 12.94% | 20 |
| LLY Stock Forecast | Eli Lilly and | Outperform |
5
|
$305.96 | $281.95 | 4.92% | 12 |
| ABBV Stock Forecast | AbbVie | Outperform |
6
|
$149.11 | $152.52 | 12.5% | 19 |
Bristol-Myers Squibb Revenue Forecast for 2022 - 2025 - 2030
In the past three years, Bristol-Myers Squibb's Revenue has seen significant growth, rising from $22.56B to $46.39B – a growth of 105.6%. In the next year, analysts believe that Revenue will reach an unimpressive $47.10B – an increase of 1.55%. By 2030, professionals predict that Bristol-Myers Squibb's Revenue will decrease by 20.45%, to a mere $36.90B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| NOVO B Stock Forecast | Novo Nordisk A/S | Hold |
5
|
kr655.00 | kr678.96 | 25.19% | 11 |
| MRK Stock Forecast | Merck | Outperform |
6
|
$94.64 | $91.73 | 0.38% | 19 |
| AZN Stock Forecast | AstraZeneca PLC | Outperform |
3
|
£104.94 | £136.08 | 39% | 13 |
Bristol-Myers Squibb Dividend per Share Forecast for 2022 - 2025 - 2030
Bristol-Myers Squibb's DPS has seen considerable growth in the last three years, rising from $1.61 to $2.01 – a growth of 24.84%. In the next year, analysts believe that DPS will reach an unimpressive $2.13 – an increase of 5.97%. For the next nine years, experts predict that Bristol-Myers Squibb's DPS will grow at a rate of 4.48%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| NOVN Stock Forecast | Novartis | Outperform |
7
|
CHF77.22 | CHF103.75 | 19.24% | 12 |
| DHR Stock Forecast | Danaher | Outperform |
5
|
$252.00 | $339.17 | 32.94% | 7 |
| MDT Stock Forecast | Medtronic | Outperform |
4
|
$105.59 | $123.50 | 15.54% | 5 |
Bristol-Myers Squibb Free Cash Flow Forecast for 2022 - 2025 - 2030
In the past three years, Bristol-Myers Squibb's Free Cash Flow has grown by 149.13%, rising from $6.12B to $15.23B. For the next year, analysts predict that Free Cash Flow will reach $20.19B – an increase of 32.5%. In 2030, professionals predict that Bristol-Myers Squibb's Free Cash Flow will decrease by 2.26%, reaching $14.89B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| SAN Stock Forecast | Sanofi | Outperform |
3
|
102.30€ | 104.66€ | 11.88% | 20 |
| AMGN Stock Forecast | Amgen | Hold |
6
|
$251.89 | $246.46 | -0.75% | 13 |
| GSK Stock Forecast | GlaxoSmithKline | Outperform |
1
|
£17.64 | £16.08 | 2.04% | 11 |
Bristol-Myers Squibb Net Income Forecast for 2022 - 2025 - 2030
Bristol-Myers Squibb's Net Income has seen impressive growth in the last three years, rising from $4.92B to $6.99B – a growth of 42.15%. In the next year, analysts believe that Net Income will reach an impressive $16.50B – an increase of 135.92%. For the next nine years, the forecast is for Net Income to grow by 90.07%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| MMM Stock Forecast | 3M | Hold |
5
|
$145.75 | $188.41 | 9.98% | 17 |
| GILD Stock Forecast | Gilead Sciences | Outperform |
5
|
$64.35 | $75.96 | 6.45% | 19 |
| MRK Stock Forecast | MERCK Kommanditgesellschaft au... | Outperform |
2
|
172.40€ | 147.51€ | 21.81% | 15 |
Bristol-Myers Squibb EBITDA Forecast for 2022 - 2025 - 2030
In the last three years, Bristol-Myers Squibb's EBITDA has seen significant growth, surging from $5.87B to $20.58B – an increase of 250.7%. In the next year, analysts predict that EBITDA will jump to $21.39B – up 3.95% from the current level. By 2030, professionals believe that Bristol-Myers Squibb's EBITDA will have decreased by an astonishing 32.53%, plummeting to just $13.89B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
8
|
$686.02 | $696.64 | 2.04% | 14 |
| BAYN Stock Forecast | Bayer | Outperform |
5
|
63.29€ | 67.79€ | 20.08% | 14 |
| 4519 Stock Forecast | Chugai Pharmaceutical | Hold |
3
|
¥3.79k | ¥0.00 | 18.73% | 0 |
Bristol-Myers Squibb EBIT Forecast for 2022 - 2025 - 2030
In the past three years, Bristol-Myers Squibb's EBIT has seen a significant increase, rising from $5.28B to $9.82B. This represents a growth of 86.09%. Analysts predict that Bristol-Myers Squibb's EBIT will increase significantly in the upcoming year, reaching $19.38B. This would represent an increase of 97.33%. Over the next nine years, experts predict that Bristol-Myers Squibb's EBIT will grow at a rate of 54.9%
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| BAS Stock Forecast | BASF | Outperform |
5
|
48.76€ | 78.27€ | 31.26% | 16 |
| ILMN Stock Forecast | Illumina | Outperform |
3
|
$240.26 | $376.81 | 45.68% | 0 |
| BAX Stock Forecast | Baxter International | Outperform |
5
|
$73.90 | $92.47 | 21.79% | 3 |
Bristol-Myers Squibb EPS Price Prediction Forecast for 2022 - 2025 - 2030
In the past three years, Bristol-Myers Squibb's EPS has seen significant growth, rising from $3.98 to $7.51 – a growth of 88.69%. In the next year, analysts believe that EPS will reach an unimpressive $7.74 – an increase of 3.06%. By 2030, professionals predict that Bristol-Myers Squibb's EPS will decrease by 8.79%, to a mere $6.85.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts |
|---|---|---|---|---|---|---|---|
| A Stock Forecast | Agilent Technologies | Outperform |
7
|
$124.41 | $172.40 | 28.61% | 2 |
| BIIB Stock Forecast | Biogen | Outperform |
4
|
$202.54 | $287.21 | 12.32% | 24 |
| COLO B Stock Forecast | Coloplast A/S | Hold |
3
|
kr929.20 | kr1.05k | 10.85% | 13 |